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Abstract  
Background: Major Depressive Disorder (MDD) is the second largest cause of global 
disease burden. It has an estimated heritability of 37% but published genome-wide 
association studies have so far identified few risk loci. Haplotype-block-based 
regional heritability mapping (HRHM) estimates the localized genetic variance 
explained by common variants within haplotype blocks, integrating the effects of 
multiple variants, and maybe more powerful for identifying MDD-associated genomic 
region.  
Methods: We applied HRHM to GS:SFHS, a large family and population based 
Scottish cohort (N=19,896). Single-SNP and haplotype-based association tests were 
used to localize the association signal within the regions identified by HRHM. 
Functional prediction was used to investigate the effect of MDD-associated SNPs 
within the regions. 
Results: A haplotype block across a 24kb region within the TOX2 gene reached 
genome-wide significance in HRHM. Single-SNP and haplotype-based association 
tests demonstrated that five out of nine genotyped SNPs and two haplotypes within 
this block were significantly associated with MDD. The expression of TOX2 and a 
brain-specific LncRNA RP1-269M15.3 in frontal cortex and Nucleus accumbens 
basal ganglia, respectively, were significantly regulated by MDD-associated SNPs 
within this region.  Both the regional heritability and single SNP-associations within 
this block were replicated in the UK-Ireland group of the most recent release of the 
Psychiatric Genomics consortium (PGC2-MDD). The SNP-association was also 
replicated in a depressive symptom sample that shares some individuals with PGC2-
MDD.  
Conclusion: This study highlights the value of HRHM for MDD and provides an 
important target within TOX2 for further functional studies.  
 
Key Words: Regional heritability; HRHM; TOX2; MDD; haplotype block; Genome-
wide analyses 
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Introduction 
Major Depressive Disorder (MDD) is ranked as the second leading contributor to the 
global disease burden in terms of the years lived with disability(1). The narrow sense 
heritability of MDD has been estimated to be approximately 37% by twin studies(2), 
suggesting a substantial contribution from genetic factors. In efforts to identify 
specific genetic risk factors for MDD, family-based linkage studies have identified 
several significant peaks in certain families, but the findings have been 
inconsistent(3). GWAS studies of unrelated participants have successfully identified 
hundreds of loci associated with other psychiatric disorders(4), but for MDD, only 
four genome-wide significant and replicable loci have been identified by two large 
GWAS studies, one on a refined MDD phenotype for Chinese Women and one on 
self-report-based depression using less intensive phenotyping in a much larger 
European sample(5-7).   
 
Several factors may be responsible for the comparatively sparse GWAS results in 
MDD. First, MDD is likely to have a highly polygenic genetic architecture where the 
disease risk is conferred by many causal variants of small effect(8,9). Combined with 
the high prevalence of MDD(10) and the possible incomplete LD between genotyped 
SNPs and causal SNPs, single-SNP based genome-wide association tests may have 
insufficient power to detect individual causal variants(11). Second, clinical 
heterogeneity has been shown in MDD between populations(6,12), and this may lead 
to difficulties in identifying causal variants across cohorts(13). Whilst GWAS sample 
sizes for MDD are increasing and efforts to refine MDD phenotype are in 
progress(5,7), alternative methodologies for detecting the signal arising from causal 
variants within and across families may also be productive.  
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Regional heritability mapping (RHM) is a method used to identify small genomic 
regions accounting for a significant proportion of the phenotypic variance in a trait of 
interest(14). In contrast to single-SNP based tests, RHM integrates effects from 
multiple SNPs by utilizing a regional genetic relationship matrix estimated from SNPs 
within a region. The matrix is constructed for each region defined by a sliding 
window across the genome, and is then used to estimate the variance explained by the 
variants within the region in a linear mixed model(14). The major advantage of RHM 
is that the regional genetic relationship matrices not only tag the effect of genotyped 
variants, but also measure the effect of un-genotyped and rare variants, including 
those associated with the SNPs but with individual effects too small to be detected by 
GWAS(14,15). Previous studies have shown that RHM has greater power to detect 
rare variants and multiple alleles in regions where GWASs provided null findings(15-
17). In 2014, Shirali .,et.al developed a haplotype-block-based heritability mapping 
(HRHM) method as an improved version of RHM. HRHM utilizes haplotype blocks 
as the unit of mapping therefore the identified blocks have less complex local LD 
structures(18).  
 
In this study, we applied HRHM to a homogenous sample of approximately 20K 
Scottish participants containing both closely- and distantly-related subjects with 
genome-wide genotyping data and a standardised structured clinical MDD 
diagnosis(19). We sought to identify genomic regions conferring risk for MDD, which 
were then further explored using single-SNP- and haplotype- based association tests. 
We then examined the functional effects of the MDD-associated SNPs within the 
identified block. Finally, replication analyses were performed in independent samples 
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for both the regional heritability and SNP association results.  
 
Methods and Materials 
The Tayside Research Ethics Committee (reference 05/S1401/89) provided ethical 
approval for the study. Participants all gave written consent, after having an 
opportunity to discuss the project, and before any data or samples were collected. 
 
Datasets 
Discovery sample: Generation Scotland: The Scottish Family Health Study 
(GS:SFHS) contains 21,387 subjects (Nmale=8,772, Nfemale=12,615; 
Agemean=47.2(SD=15.1)), who were recruited from the registers of collaborating 
general practices in Glasgow, Tayside,  Ayrshire, Arran and Northeast regions of 
Scotland. At least one first-degree relative aged 18 or over was required to be 
identified for each participant(19,20). A structured clinical interview was used for the 
diagnosis of lifetime DSM-IV mood disorders (SCID)(21,22). Details of MDD 
diagnosis, genotyping, quality control (QC) and imputation methods are described in 
the Supplement. In total 561,125 genotyped and 8,642,105 post-imputation autosomal 
SNPs passed QC criteria were available for 19,896 participants (2,659 MDD cases 
and 17,237 controls) for subsequent analyses. 
 
Replication sample 1: UK Biobank 
Data used in this study were provided as part of UK Biobank project reference #4844. 
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Details for genotyping, quality control, imputation and phenotyping are described in 
the Supplement. In brief, genotyping data was available for 152,729 UK Biobank 
participants recruited in United kingdom(23).  The probable MDD phenotype was 
created based on the putative MDD definition established in Smith et al(2013) using 
responses to a touchscreen questionnaire (UK Biobank 2011b)(24), from self-report 
information, and from inpatient records via linkage to hospital episode data 
(Supplement). After quality control and removing subjects who were in both 
GS:SFHS and UK Biobank datasets, and one of each pair of close relatives 
(relatedness > 0.05) of GS:SFSHS participants or the remained UK Biobank 
participants, 1,198,327 SNPs for 24,015 subjects with putative MDD phenotype 
available (8,143 cases and 15,872 controls) remained in downstream analyses.   
 
Replication sample2: PGC Major Depression Dataset (PGC2-MDD) 
The Psychiatric Genomics Consortium provided individual genotypes (best guess) of 
imputed SNPs for participants from 22 cohorts in PGC2-MDD(Table s1). All cases 
met DSM-IV criteria for life MDD, the majority of them were ascertained clinically. 
Most control samples were screened and participants with lifetime MDD were 
removed(Table s1).  Details for genotyping, quality control, imputation and 
phenotyping are described in the Supplement. After quality control and removing 
subjects overlapped with GS:SFHS and UK Biobank dataset, 32,554 subjects of 
European ancestry (13,261 cases and 19,293 controls) were used in downstream 
analysis. Consistent with earlier work(25,26), we grouped the 22 cohorts into 7 
groups based on the country of ancestor information for regional heritability 
analysis(Table s1). 
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Replication sample3:  Depressive symptom datasets (DS) (this sample contains 
overlapping individuals with replication sample 1 and 2) 
Okbay et.al(2016) carried out a GWAS meta-analysis (N = 180,866) on three samples 
using depressive symptoms as the trait of interest (27). The ascertained MDD 
diagnosis information was available for two samples (PGC1-MDD(Ncases = 9,240, 
Ncontrols = 9,519) and the Resource for Genetic Epidemiology Research on Aging 
(GERA, Ncases = 7,231, Ncontrols = 49,316))(27). For the third sample (UK Biobank (N 
= 105,739)), a continuous phenotype measuring the severity of depressive symptom 
had been created and used in the meta-analysis(27). Whilst this sample overlapped 
with the PGC2-MDD and UK Biobank samples, it provided results based upon a non-
diagnostic quantitative measure of depressive symptoms and involved another large 
cohort, GERA(27). 
 
Genome-wide haplotype-block-based Regional Heritability Mapping (HRHM) 
Regional heritability mapping (RHM) is a method for detecting localized genomic 
regions where genetic variants contribute significantly to the variation of phenotype 
of interest(14). As an improved version of RHM, HRHM divides the genome into 
haplotype-blocks, based on the recombination hotspots in the genome(18). Details of 
HRHM are described in the Supplement. In brief, in GS:SFHS the genotyped SNPs 
were mapped to 49,637 haplotype-blocks across the genome and the regional 
heritability was estimated and tested for each of the haplotype-blocks. A standard 
‘two-GRM’ model incorporates two genomic relationship matrices (GRM); a regional 
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genomic relationship matrix (rGRM) estimated from SNPs in the haplotype block and 
a complement genomic relationship matrix (cGRM) estimated from all SNPs that are 
not included in in the haplotype block. These GRMs were jointly fitted as random 
effects in LMM. Covariates fitted as fixed effects include age, age2, sex, 20 principal 
components. A Log likelihood ratio test (LRT) is applied to test the significance of 
random effect represented in rGRM by comparing a model with both cGRM and an 
rGRM fitted against a model including the cGRM but without an rGRM fitted. The 
genome-wide significance threshold for P values from LRT is 1.01x10-
6(NBonferroni=49,637). This two-GRM model, while providing an unbiased estimate of 
regional heritability, was highly computationally demanding. To improve the 
calculation efficiency, a pre-adjustment strategy was applied in the genome-wide 
HRHM (Supplement). For haplotype-blocks that exceeded the genome-wide 
significant threshold, we re-tested the block using the two-GRM model to provide an 
accurate estimation of regional heritability in the target block. All the analyses were 
performed in REACTA(14,28). According to the GCTA-GREML Power Calculator, 
this study is well-powered for the GREML-based SNP heritability analysis 
(99.88%)(29). 
 
Localized association tests for the significant haplotype block identified by 
HRHM in GS:SFHS 
HRHM identified a significant block chr20:42555671-42579473, we performed a 
series of association tests to localize the association signals within this block in 
GS:SFHS.  
1) Single-SNP-based association test for common SNPs within the identified 
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haplotype-block.  
Association tests were performed on genotyped and imputed common SNPs located 
in the significant haplotype-block chr20:42555671-42579473 using GCTA-MLMA 
(linear mixed model based association analysis)(30). The SNP effect was tested as a 
fixed effect, other covariates included age, age2, sex and 20 PCs. To prevent the 
estimates of SNP effects from being confounded by the polygenic component and 
family structure, cGRM and cGRMkin were fitted simultaneously as random effects in 
the model(31). cGRM (complement-snp-set GRM) was the genomic relationship 
created matrix using all of the genotyped SNPs excluding the SNPs in the hit block; 
cGRMkin was the kinship relationship matrix (representing pedigree-associated 
genetic variation). cGRMkin was created by setting elements in cGRM that were less 
than or equal to 0.05 to 0(31). The estimated fixed effect (on the linear scale) was 
transformed to logit and liability scale using Taylor series approximation(32). 
Bonferroni multiple-testing-correction was performed for the P values for each SNP.  
 
2) Single-haplotype-based association test 
Single-haplotype-based association tests were performed for the common haplotypes 
(Frequency≥0.01) derived from the nine genotyped common SNPs located in the 
significant haplotype-block chr20:42555671-42579473 using GCTA-MLMA(30) for 
the full dataset and an unrelated dataset, and using famLBL(33) for a subset 
consisting of case-parent trios in GS:SFHS. Details of single-haplotype-based 
association test are described in the Supplement.  
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Functional effects of MDD-associated-SNPs in the significant block 
The significant haplotype-block chr20:42555671-42579473 is located in the intron 
region and a proportion of an adjacent exon of gene TOX2. To investigate the 
potential functional effects from variants within this block, we imputed the 9 
genotyped SNPs within this block to 53 common SNPs based on HRC reference, all 
of them are non-coding SNPs. We performed single-SNP-based association test for 
each of them with MDD using GCTA-MLMA (the same method for genotyped 
SNPs). This identified 38 imputed SNPs significantly associated with MDD. We then 
examined the functional role of the 38 SNPs using the following functional annotation 
tools and analyses: the potential to affect the binding of transcription factors in 
Regulomedb(34), Genome Wide Annotation of VAriants(GWAVA), Genomic 
Evolutionary Rate Profiling (GERP)(35), brain-tissue-specific allelic effect on gene-
expression(eQTL analysis) based on GTEX and BRAINEAC, and brain-tissue-
specific allelic effect on DNA methylation in CpG loci(meQTL analysis). Details of 
these tools and analyses are described in the Supplement.  
 
Replication analysis 
Regional heritability in the significant block identified in GS:SFHS 
Individual genotypes in UKbiobank and PGC2-MDD(22 cohorts) were used to 
estimate the regional heritability of the target haplotype block in the two samples. The 
two-GRM model (rGRM+cGRM) was applied to provide accurate estimates. For 
PGC2-MDD, the regional heritability was estimated for each of the 7 groups defined 
based on country of ancestor (Table s1) as well as for the combined dataset. 
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Single-SNP based association test for the five significant SNPs(genotyped) within the 
significant block identified in GS:SFHS 
For UK Biobank the single-SNP-based association tests were performed using a 
logistic model in PLINK(36). Covariates included age, sex, centre, batch and 15 
principal components provided by UK Biobank. For PGC2-MDD the association test 
was performed using a logistic model for each individual cohort. Covariates include 
sex and 20 principal components (the age variable was not yet available for the full 
dataset at the time of this study). Meta-analysis was performed across all cohorts in 
each group to generate group-level association statistics. The meta-analysis was 
performed using the ‘metagen’ function in R package ‘meta’. For the DS sample the 
GWAS summary statistics were downloaded from the website of social science 
GWAS consortium (http://www.thessgac.org/#!data/kuzq8).  
 
Results 
Genome-wide Haplotype-block-based regional Heritability Mapping (HRHM) was 
carried out for 49,637 haplotype-blocks using 56,1125 genotyped common SNPs in 
GS:SFHS for MDD (Ncase=2,659, Ncontrol=17,237). The regional heritability from each 
haplotype-block was tested using a pre-adjusted-GRM strategy in the linear mixed 
model. The Manhattan plot and qqplot for the LRT are shown in Figure 1. One 
haplotype-block covering a 24kb region in the intron region and a proportion of an 
adjacent exon of gene TOX2 exceeded the genome-wide significant threshold 
(PBonf_threshold=1.01x10
-6
): hg19:chromosome20:42555671-42579473 (Plrt=8.86x10
-7) 
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(Figure 1). The two-GRM model confirmed the significance of this haplotype-block 
(Plrt=5.6 x10
-7) and the regional heritability (  
 ) was estimated to be 0.008(0.006).  
The regional heritability of this block was more significant in females MDD 
(  
 =0.009, se=0.007, Plrt=5.64x10
-5, Ncase=1,893, Ncontrol=9,818) than in males MDD 
(  
  0.003, se=0.004, Plrt=0.02, Ncase=765, Ncontrol=7,420).  
 
We further performed a series of association tests to disentangle the signal detected by 
HRHM in the significant block. Using the single-SNP-based association test, five of 
the nine genotyped common SNPs within the hit block were significantly associated 
with MDD (Table 1, s2). The five significant SNPs were in high linkage 
disequilibrium (LD) with each other (Figure 1D) and their minor alleles showed a 
consistent negative effect on the risk of MDD with the odds ratio ranging from 0.785 
to 0.833(Table 1). Haplotype-based association tests for haplotypes derived from the 
nine SNPs showed that two out of the seven common haplotypes (frequency ≥ 0.01) 
were associated with MDD. One of these haplotypes contains the minor (protective) 
alleles of the five single-SNP-level significant SNPs and one contains the major (risk) 
alleles. The size and the direction of the effects of the two haplotypes were consistent 
with that estimated from the single-SNP based tests (odds ratio: 0.792 for the 
protective haplotype and 1.232 for the risk haplotype) (Table 2). Additional 
association tests on sub datasets (unrelated and case-parents-trio) showed that the risk 
haplotype was significantly associated with MDD in the unrelated dataset (Table s3), 
whereas the protective haplotype was significant in case-parents-trio dataset (Table 
s4).  
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The significant block overlapped with an enhancer active in multi-tissues and cell 
lines including astrocytes (Figure 2A)(37), and multiple alternative transcription start 
sites (TSSs) including a TSS primarily expressed in thalamus (the TSS labeled as 
‘p3@TOX2’ in Figure 2A)(37), suggesting a potential regulatory role. To link the 
association signal from single variants with the potentially functional effects of those 
variants on disease-relevant biological processes, we identified 38 imputed SNPs in 
the target block significantly associated with MDD (Table s5), and predicted their 
potentially regulatory function using multiple predictors and statistics of non-coding 
DNA function, including the likelihood of affecting transcription factor binding, 
multi-genome-wide properties, evolutionary conservation, the cis-effect on gene 
expression of genes within a distance of 1MB and on DNA methylation. Among the 
38 SNPs, two of them were annotated to be ‘likely to affect TF binding’ (score=2b) by 
regulomeDB, five obtained a GWAVA-TSS score  ≥ 0.5 (suggesting ‘functional’) and 
five obtained a GERP-score >2 (suggesting ‘constrained’) (Table s6). Tissue-specific 
snp-cis-gene-expression (cis-eQTL) analyses were performed for the 38 SNPs using 
11 brain tissues from GTEX and 10 brain tissues from BRAINEAC. The results from 
GTEX showed that the genotype of 30 of the 38 SNPs significantly stratify the 
expression of gene RP1-269M15.3 (LncRNA) in the tissue ‘Nucleus accumbens basal 
ganglia’ with the minor alleles significantly up-regulating the RNA expression level 
(Table s7)(Figure 2B). The results from BRAINEAC suggested that all of the 38 
SNPs significantly stratify the expression of gene TOX2 in frontal cortex (minor allele 
induces up-regulation) (Figure 2C) and gene C20orf62 (LncRNA) (minor allele 
induces down-regulation) in Cerebellar cortex (Table s8,s9). The results from meQTL 
analysis suggested that 30 of the 38 SNPs are significant meQTL SNPs in frontal 
cortex, and that particularly 19 of them significantly stratify DNA methylation of a 
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CpG locus cg24403644 (minor allele induces hypo-methylation) (Table s10).  
cg24403644 is located in a cluster of TSSs in TOX2 (Figure 2) and shows differential 
methylation between human fetal and postnatal lifetime in frontal cortex and during 
the fetal brain development(38,39). Among significant SNPs in the cis-eQTL and cis-
meQTL analyses, rs79645278 located in the peak of active enhancer (in astrocytes 
and other cell lines), and was predicted to be ‘likely to affect TF binding’ (2b) in 
RegulomeDB, having a GWAVA-TSS score of 0.5 and a GERP-score of 2.31(Figure 
2A,B,C, Table s6).  
 
The regional heritability detected in the hit block was replicated in the UK-Ireland 
group in PGC2-MDD with nominal significance (Plrt=0.049,   
 =0.001,se=0.001), 
whilst it was not significant in other groups in PGC2-MDD and UK Biobank (Table 
s11). The single-SNP-based association test for the five significant SNPs (genotyped) 
in this block identified in GS:SFHS showed that all five were replicated in the DS 
sample; all five were also replicated in the UK-Ireland group in PGC2-MDD (Table 1. 
Results for individual cohorts were shown in Table s12 and Figure s1), but not in 
other PGC2-MDD groups or in the meta-analysed combined PGC2-MDD sample 
(Table s13); none of the five SNPs were replicated in the UK Biobank sample but all 
showed the same consistent direction of effect with that reported in the discovery 
sample (Table 1, Figure s1). Meta-analysis using all independent UK-Ireland 
replication samples (UK Biobank + 4 cohorts in PGC2-MDD-UK_Ireland) showed 
that all of the five SNPs reached nominal significance (Table s13, consistent sign with 
GS:SFHS as shown in Figure 3, using SNP rs6093898 as an example.  
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Discussion 
The current study used a combination of genome-wide haplotype-block-based 
regional heritability mapping (HRHM), localized association tests and functional 
prediction to identify candidate genomic region associated with MDD. Using a large 
Scottish cohort GS:SFHS, a genome-wide significant haplotype block located in gene 
TOX2 was identified by HRHM as a risk region for MDD. Association tests using 
both single SNPs and haplotypes within this block highlighted candidate contributing 
genetic variants for MDD. Replication analyses showed that the regional heritability 
in this block was nominally significant in the UK-Ireland groups in PGC2-MDD. The 
SNP-level association signals within the hit block were replicated in the UK-Ireland 
group in PGC2-MDD and a study of depressive symptom (DS) which has overlapping 
subjects from PGC2-MDD and UK Biobank. 
 
As shown in this study, compared with single-SNP-based genome-wide association 
methods (GWAS), HRHM provided following advantages: (1) a smaller number of 
tests were performed therefore a less stringent threshold of genome-wide significance 
was applied. (2) Haplotype blocks rather than single SNPs were the unit of mapping, 
these are therefore relatively less dependent on the density of the genotype arrays and 
do not require the same SNPs to be typed or imputed in replication study. (3) HRHM 
applied a linear mixed model accounting for both polygenic component and family 
structure, and can be applied to both population and family data. (4) Since haplotype 
blocks were used as the unit of mapping, the identified locus has a less complex LD 
structure (Figure 1D), which will benefit the downstream identification of candidate 
variants.  
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To date, published GWASs have mapped associated variants to very few genes for 
MDD (LHPP, SIRT1, TMEM161B–MEF2C and NEGR1)(5,7). In this study, the 
identified haplotype block was located in gene TOX2 (TOX high mobility group box 
family member 2, also known as GCX1), indicating a new candidate gene for MDD. 
TOX2 is a putative transcriptional activator involved in the hypothalamo-pituitary-
gonadal system(40), and is located in a large genomic region which has been 
previously reported as associated with depression symptoms in psychotic 
illness(41,42). The same locus has also been weakly-associated with conduct disorder 
in a previous study(43). Using available databases, we found that convergent evidence 
from TSS by Fantom5 annotation (Figure 2A), histone modification markers and 
Dnase peaks representing active enhancers by ENCODE annotation (Figure 2A), and 
transcription factor binding prediction by RegulomeDB (Table s6) suggested a 
regulatory function of this block. To test for the potential effects of the variants within 
the block on gene expression, we performed brain-tissue specific cis-QTL analysis for 
SNPs significantly associated with MDD within the block. The expression of a 
LncRNA RP1-269M15.3 was significantly up-regulated by the minor alleles (minor 
alleles are protective to MDD as shown in Table 1, s5) of candidate SNPs within the 
block in Nucleus Accumbens, a tissue having been previously implicated in 
MDD(44). RP1-269M15.3 was a multi-exon LncRNA with a multi-species conserved 
region (Figure s2A) and was only expressed specifically in brain tissues (Figure s2B) 
and therefore of potential function in brain tissues. Similarly, the expression of gene 
TOX2 was significantly up-regulated by the minor alleles of candidate SNPs in frontal 
cortex, a relevant tissue of MDD as well (45). The regulatory effect of MDD-
associated SNPs in gene TOX2 in frontal cortex is further supported by the meQTL 
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analysis on the same tissue. Combined with the fact that all of the 19 SNPs are both 
meQTL and eQTL SNPs for gene TOX2 in frontal cortex and the fact that hypo-
methylation has been previously suggested to be correlated with up-regulation of gene 
expression(46), consistent evidence from both methylation and gene expression data 
indicated that the minor alleles (protective) of MDD-associated SNPs up-regulate the 
gene expression of TOX2 in frontal cortex(Table s8,s10).  Interestingly, the brain-
specific expression of both RP1-269M15.3 and TOX2 were highly correlated (r ≥ 0.7) 
with a number of depression-related genes (for example, LRFN5, GRM7, 
CRH)(47,48) in brain development (http://brainspan.org) (Table s14, s15), suggesting 
that the expression networks involving those genes were potential targets of the 
effects from candidate variants. These results are consistent with a previous study 
suggesting an overrepresentation of MDD GWAS significant loci in CNS expression 
and the regulation of gene expression in CNS during development(7).  
 
The regional heritability in the identified block was nominally significant only in the 
UK-Ireland group of PGC2-MDD. The five significant genotyped SNPs within the 
block identified in GS:SFHS were replicated in DS sample and in the UK-Ireland 
group in PGC2-MDD. UK Biobank sample failed to replicate any of them, although 
they showed consistent sign of effect. Those results are likely attributable to the 
phenotyping differences (diagnosed MDD in GS:SFHS, mostly diagnosed MDD in 
PGC(49), putative MDD in UK Biobank and depressive symptom in DS), and the 
clinical heterogeneity within MDD across PGC2-MDD groups as shown in Table 
s10)(12). Notably, UK-Ireland which shows the most consistent replication results are 
from the same country/region with GS:SFHS, so its cohorts are likely to have a 
 18 
similar local genomic recombination pattern and LD structure with GS:SFHS and 
potentially carry alleles not common in other European cohorts, which may explain 
the better replication result from this group (Figure 3,s1).   
 
There are, however, several limitations in the current study. Firstly, the re-adjustment 
strategy applied to genome-wide HRHM, whilst it reduced the computational burden, 
it was potentially excessively conservative in reporting true associations (observed 
LRT statistics were depleted from expectation, as shown in Figure 1D), which 
consequently reduced the power of HRHM(50). Secondly, phenotypic difference 
among discovery and replication samples impeded the complete replication of 
findings across all samples. UK Biobank samples are also from the same 
country/region as GS:SFHS, as are the UK-Ireland group of PGC2-MDD, but 
currently UK Biobank only have putative MDD information available for a small 
subset of genotyped participants. Ongoing clinical assessment of MDD and the 
genotyping work on this sample will potentially provide more power to the replication 
analysis for our findings in future data releases.  
 
Conclusion 
The present study showed the first application of genome-wide HRHM to a 
psychiatric disorder. A genome-wide significant region was identified by HRHM and 
the contributing genetic effect was localized to variants and haplotypes within the 
block. The results were partly replicated in two independent samples. Functional 
prediction and cis-eQTL analyses suggested that the genotype of associated-variants 
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within the block stratified the gene expression of a potentially functional LncRNA 
RP1-269M15.3 and gene TOX2 in MDD-relevant brain tissues, which should be 
explored in further studies. 
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Legends 
Figure 1 Genome-wide haplotype-block-based regional heritability mapping(HRHM) 
results on MDD in GS:SFHS. A: Manhattan plot. Each point represents a haplotype 
block. The location of the point is the mid-position of the haplotype block. B: qqplot 
for the LRT. The LRT statistics distributed as a mixture of 0 and chi-squared (df=1) 
distribution. C: zoom in region of the hit haplotype block region in Chromosome 20. 
D: LD structure within the hit haplotype block in GS:SFHS. The block is located in 
gene TOX2, it contains nine genotyped common SNPs(blue box) and five of them are 
in high LD(red arrow) in GS:SFHS. 
 
Figure 2 Functional prediction of the hit haplotype block. A: functional annotation of 
the hit block. The hit haplotype block (red bar on the left top showing the block and 
blue bars showing the genotype SNPs in GS:SFHS) is located in the intron region and 
a proportion of an adjacent exon of gene TOX2, overlapped with Fantom5 enhancers 
and Transcription start sites, and regulatory-relevant histone modification 
peaks(H3K27Ac and H3K4Me1). Within the block, 38 imputed SNPs were associated 
with MDD, using SNP rs79645278(pink) as an example. This SNP is located in the 
peak of active enhancer in astrocyte(highlighted with blue line). B,C: boxplots 
showing tissue specific effect from SNPs that are both associated with MDD in 
GS:SFHS and gene expression, using SNP rs79645278 as an example. B: the minor 
allele of rs79645278 up-regulates the expression of a LncRNA RP1-269M15.3 in the 
tissue ‘Nucleus accumbens basal ganglia’. C: the minor allele of rs79645278 up-
regulates the expression of gene TOX2 in Frontal cortex. Abbreviations: cerebellar 
cortex (CRBL), frontal cortex (FCTX), hippocampus (HIPP), medulla (specifically 
inferior olivary nucleus, MEDU), occipital cortex (specifically primary visual cortex, 
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OCTX), putamen (PUTM), substantia nigra (SNIG), thalamus (THAL), temporal 
cortex (TCTX) and intralobular white matter (WHMT). 
 
Figure 3 Forest plot showing meta-analysis for single-SNP-based association test on 
GS:SFHS and all UK/Ireland replication samples(four PGC2-MDD cohorts and UK 
biobank), using SNP rs6093898 as an example. 
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Table 1. Single-SNP-based association test results for five MDD-associated SNPs in discovery and replication samples. 
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Haplotype Frequen
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P Adjusted 
P 
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CT 
0.120 0.026 0.005 1.23
2 
0.209 0.058 2.47E-
06 
1.73E-05 
* 
GGGTGGT
CC 
0.094 -0.024 0.006 0.79
2 
-
0.233 
0.046 5.77E-
05 
4.04E-04 
* 
TAGCAAC
CT 
0.118 -0.010 0.005 0.91
1 
-
0.093 
0.045 6.10E-
02 
4.27E-01 
TAGCGAC
TC 
0.311 0.006 0.004 1.05
2 
0.051 0.035 1.24E-
01 
8.71E-01 
GAGCAAC
CT 
0.012 -0.012 0.016 0.89
7 
-
0.109 
0.131 4.60E-
01 
1.00E+0
0 
TAGCAAC
CC 
0.015 -0.010 0.014 0.91
6 
-
0.088 
0.120 5.05E-
01 
1.00E+0
0 
TATCGACT
C 
0.304 -0.002 0.004 0.98
0 
-
0.020 
0.033 5.59E-
01 
1.00E+0
0 
 
Table 2 Haplotype-based association test results for common haplotypes derived from 
the nine genotyped common SNPs in GS:SFHS. 
Adjusted P:  Bonferroni  method adjusted P values. 
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